Denali Therapeutics Inc. — Q1 2019 Form 10-Q
Reporting period: Three months ended March 31, 2019; balance-sheet comparisons are against December 31, 2018. Denali is an early clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases. It reported no product sales; revenue was from collaborations.
Financial performance and liquidity
| Metric | Q1 2019 | Q1 2018 / prior date |
|---|---|---|
| Collaboration revenue | $4.2 million | $0.6 million |
| Research and development expense | $37.4 million | $20.8 million |
| General and administrative expense | $9.3 million | $5.6 million |
| Operating loss | $42.5 million | $25.7 million |
| Net loss | $39.0 million; $0.41 per share | $23.7 million; $0.26 per share |
| Cash used in operating activities | $30.3 million | Cash provided: $33.6 million |
- Revenue comprised $3.5 million from Sanofi and $0.7 million from Takeda. Denali recognized no product sales or Sanofi milestones.
- Cash, cash equivalents and marketable securities totaled $583.0 million at March 31, 2019. Cash and cash equivalents were $39.7 million; marketable securities were $543.4 million.
- Current assets were $499.5 million and current liabilities $43.2 million, implying working capital of approximately $456.3 million. Accumulated deficit was $266.9 million.
- Total liabilities were $159.9 million. The balance sheet included $72.2 million of operating lease liabilities and $68.0 million of contract liabilities. The filing does not provide a clear separate borrowings or debt balance.
- No gross profit or product margin was reported; the company had no product revenue. Operating losses continued as research and corporate expenses exceeded collaboration revenue.
Changes and notable items
- Collaboration revenue increased $3.6 million year over year, primarily due to Sanofi. Operating expenses rose 77%; R&D increased 80% and G&A 67%. Net loss increased 65%.
- R&D growth reflected higher personnel and stock-based compensation, broader pipeline investment, clinical progression of LRRK2 and RIPK1 programs, and new-headquarters costs.
- Operating cash flow shifted from a $33.6 million inflow to a $30.3 million outflow. The 2018 period included a $60.0 million increase in Takeda-related contract liabilities; Q1 2019 did not have a comparable upfront collaboration cash inflow.
- Denali adopted the new lease accounting standard in January 2019, recording operating lease assets and liabilities. This affects balance-sheet comparability with prior periods; management said adoption did not materially affect reported operations or equity.
Outlook, risks and commitments
- Management expects significant losses and rising R&D spending for the foreseeable future, with no product revenue expected unless and until a candidate is approved and commercialized. No specific quarterly or annual financial guidance was provided.
- Management stated that available cash, cash equivalents and marketable securities were expected to fund projected operations for at least 12 months, while noting that estimates depend on assumptions and additional funding may be needed.
- Pipeline status included DNL201 in a Phase 1b Parkinson’s study, DNL151 in a Phase 1 healthy-volunteer trial, and DNL747 in Phase 1b studies for ALS and Alzheimer’s disease. Denali planned to file a CTA or IND for DNL310 in late 2019; it had received orphan drug and rare pediatric disease designations.
- Key risks include clinical failure or delay, safety findings, regulatory uncertainty, reliance on collaborators and third-party manufacturers, financing needs, competition, and intellectual-property protection. The filing notes prior liver-test abnormalities led to discontinuation of DNL104; DNL201 had previously been subject to a partial clinical hold that was removed in 2017.
- Commitments include a 10-year headquarters lease and $25.4 million of non-cancellable Lonza development and manufacturing purchase orders. F-star agreements could require contingent milestone payments of up to $447.0 million in aggregate; these were not recognized at acquisition and would be expensed if incurred.
- Management reported no material litigation and concluded disclosure controls were effective at a reasonable assurance level.
Important facts for investors to verify
- Whether clinical-trial progress, safety, enrollment and biomarker results support the stated development plans and anticipated timelines.
- How quickly the $583.0 million liquidity pool is consumed as R&D spending and operating losses increase, and whether additional financing becomes necessary.
- The timing and accounting of future Takeda and Sanofi collaboration revenue, milestones, cost-sharing obligations and any partner option decisions.
- The full cash impact of lease obligations, Lonza commitments and contingent F-star milestone payments.
- Whether intellectual-property rights, manufacturing capacity and external suppliers can support development of the pipeline and BBB platform.